Table 2.
The effects of resveratrol on 5-HT and 5-HIAA contents in the brain and intestine of irritable bowel syndrome (IBS) rats.
| Group | Concentration (ng/g) | |||
|---|---|---|---|---|
| 5-HT | 5-HIAA | 5-HIAA/5-HT | ||
| Hippocampus | Control + vehicle | 228.90 ± 19.54 | 68.46 ± 7.17 | 0.30 ± 0.37 |
| CACS + vehicle | 147.51 ± 12.70** | 92.80 ± 3.57* | 0.63 ± 0.28** | |
| CACS + RES 10 | 146.00 ± 9.87 | 80.83 ± 6.08 | 0.55 ± 0.62 | |
| CACS + RES 20 | 182.90 ± 10.60 | 77.82 ± 4.41 | 0.43 ± 0.42# | |
| CACS + RES 40 | 196.55 ± 14.78# | 76.84 ± 2.54# | 0.39 ± 0.17# | |
| CACS + FLU 10 | 197.30 ± 13.74# | 80.85 ± 5.67 | 0.41 ± 0.41 | |
| Ileum | Control + vehicle | 1209.05 ± 144.78 | 220.85 ± 12.67 | 0.20 ± 0.04 |
| CACS + vehicle | 1632.35 ± 109.99* | 163.26 ± 18.53* | 0.10 ± 0.02* | |
| CACS + RES 10 | 1436.12 ± 115.19 | 167.15 ± 21.54 | 0.12 ± 0.02 | |
| CACS + RES 20 | 1289.35 ± 112.43 | 178.50 ± 23.26 | 0.15 ± 0.02 | |
| CACS + RES 40 | 1173.85 ± 163.23# | 170.07 ± 27.27 | 0.17 ± 0.04 | |
| CACS + FLU 10 | 1204.11 ± 97.05# | 178.20 ± 24.52 | 0.17 ± 0.03 | |
| Colon | Control + vehicle | 2231.43 ± 312.65 | 148.57 ± 10.80 | 0.07 ± 0.01 |
| CACS + vehicle | 3462.86 ± 253.12* | 116.73 ± 22.39 | 0.04 ± 0.01* | |
| CACS + RES 10 | 2822.61 ± 309.11 | 106.12 ± 8.01 | 0.04 ± 0.00 | |
| CACS + RES 20 | 2591.75 ± 383.80 | 125.47 ± 21.18 | 0.05 ± 0.01 | |
| CACS + RES 40 | 2131.02 ± 309.48## | 143.25 ± 23.49 | 0.07 ± 0.02# | |
| CACS + FLU 10 | 2514.13 ± 117.03# | 114.91 ± 16.14 | 0.05 ± 0.01 | |
RES, resveratrol; FLU, fluoxetine. Values were expressed as mean ± SEM of six rats. *P < 0.05 and **P < 0.01, compared to vehicle treated control rats. #P < 0.05 and ##P < 0.01, compared to vehicle treated chronic acute combining stress (CACS) rats.